Clinical Study Reports for Medical Devices

Report Development

ICH E3 Structure Applied to Medical Device Clinical Reports

ICH E3, the international guideline for structure and content of clinical study reports, provides the most widely accepted framework for CSR organization. While ICH E3 was developed in the pharmaceutical context, FDA expects device CSRs to follow a similar structure: study synopsis, introduction, study objectives, investigational plan, study population, efficacy results (safety and effectiveness for devices), statistical analysis methods, discussion and conclusions, and appendices including the protocol, SAP, and TLFs.

Device-specific CSR elements that differ from drug reports include the investigational device description and accountability procedures, operator training documentation, device performance outcome analyses separate from clinical endpoint analyses, and device-related adverse event categorization. We write CSRs with the FDA clinical reviewer's reading sequence in mind — the synopsis and results sections are written to communicate key findings clearly before the reviewer has read the full body of the report.

Clinical Sections for 510(k) and PMA Submissions

The relationship between the CSR and the FDA submission varies by pathway. For a 510(k) with a clinical study, the clinical section typically summarizes the study design, primary endpoint results, and safety data in condensed form — the full CSR is appended. For a PMA, the clinical section is a comprehensive evidence summary that FDA reviewers use as the primary document, with the full CSR and individual patient data available as supporting documentation. The scope of writing required for each pathway is different, and the framing of clinical evidence relative to the legal standard — substantial equivalence for 510(k), reasonable assurance of safety and effectiveness for PMA — must be explicit in the clinical section narrative.

FDA's Summary of Safety and Effectiveness Data (SSED) for approved PMA devices provides a template for what the clinical evidence summary should contain. We use approved SSEDs for comparable device types as benchmarks when structuring PMA clinical evidence sections — writing to the standard that FDA has already accepted for the device category.

Literature-Based Clinical Evidence: When There Is No Sponsored Study

Not every 510(k) or De Novo submission involves a sponsored clinical investigation. Literature-based clinical evidence — systematic literature reviews, meta-analyses, and clinically relevant published studies — can support substantial equivalence when the literature is relevant and the methodology is sound. FDA's guidance on use of published literature in 510(k) submissions identifies the criteria for acceptable literature evidence: study design, device comparability, patient population, and endpoint relevance. We develop literature-based clinical evidence packages that address these criteria explicitly, with a literature search strategy documented to FDA's requirements.

What We Deliver

• Full clinical study report (CSR) in ICH E3 structure
• Study synopsis and executive summary
• Safety and effectiveness results narrative with TLF integration
• 510(k) clinical section writing and integration with submission
• PMA clinical evidence summary aligned to SSED structure
• Literature review and clinical evidence package for non-sponsored study submissions
• Clinical section of De Novo request for devices without precedent
• IDE final report consistent with 21 CFR 812.150

Start Your Clinical Report